Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3038% below fair value
$18.41+0.01 (+0.05%)
Close on Nov 19, 2026Market cap $1.33BP/E 9.3Yield –
Innoviva shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Innoviva's shares outstanding was 72M at Sep 30, 2026. For fiscal 2025 it was 85M, up 14.3% from the year before. Over ten years it grew -3.0% a year on average. The highest annual figure on record is 123M in fiscal 2016.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 85M | +14.3% |
| FY2024 | Dec 31, 2024 | 74M | -14.6% |
| FY2023 | Dec 31, 2023 | 87M | -8.8% |
| FY2022 | Dec 31, 2022 | 95M | +1.0% |
| FY2021 | Dec 31, 2021 | 94M | -16.9% |
| FY2020 | Dec 31, 2020 | 114M | +0.1% |
| FY2019 | Dec 31, 2019 | 113M | +0.0% |
| FY2018 | Dec 31, 2018 | 113M | -5.4% |
| FY2017 | Dec 31, 2017 | 120M | -2.7% |
| FY2016 | Dec 31, 2016 | 123M | +6.8% |
| FY2015 | Dec 31, 2015 | 115M | +3.0% |
| FY2014 | Dec 31, 2014 | 112M | +9.4% |
| FY2013 | Dec 31, 2013 | 102M | +12.7% |
| FY2012 | Dec 31, 2012 | 91M | +10.8% |
| FY2011 | Dec 31, 2011 | 82M | +13.8% |
| FY2010 | Dec 31, 2010 | 72M | +14.3% |
| FY2009 | Dec 31, 2009 | 63M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 72M | -15.2% |
| Q2 FY2026 | Jun 30, 2026 | 73M | -13.1% |
| Q1 FY2026 | Mar 31, 2026 | 85M | +35.3% |
| Q4 FY2025 | Dec 31, 2025 | 85M | -20.8% |
| Q3 FY2025 | Sep 30, 2025 | 85M | +35.0% |
| Q2 FY2025 | Jun 30, 2025 | 84M | +35.1% |
| Q1 FY2025 | Mar 31, 2025 | 63M | -25.8% |
| Q4 FY2024 | Dec 31, 2024 | 108M | +26.7% |
| Q3 FY2024 | Sep 30, 2024 | 63M | -26.9% |
| Q2 FY2024 | Jun 30, 2024 | 63M | -4.5% |
| Q1 FY2024 | Mar 31, 2024 | 85M | -5.9% |
| Q4 FY2023 | Dec 31, 2023 | 85M | -11.3% |
| Q3 FY2023 | Sep 30, 2023 | 86M | -10.1% |
| Q2 FY2023 | Jun 30, 2023 | 65M | -31.5% |
| Q1 FY2023 | Mar 31, 2023 | 90M | -4.2% |
| Q4 FY2022 | Dec 31, 2022 | 96M | +17.3% |
| Q3 FY2022 | Sep 30, 2022 | 96M | +17.3% |
| Q2 FY2022 | Jun 30, 2022 | 96M | -5.0% |
| Q1 FY2022 | Mar 31, 2022 | 94M | -17.5% |
| Q4 FY2021 | Dec 31, 2021 | 82M | -28.1% |
| Q3 FY2021 | Sep 30, 2021 | 82M | -28.1% |
| Q2 FY2021 | Jun 30, 2021 | 101M | -11.4% |
| Q1 FY2021 | Mar 31, 2021 | 114M | +0.1% |
| Q4 FY2020 | Dec 31, 2020 | 114M | +0.1% |
| Q3 FY2020 | Sep 30, 2020 | 114M | +0.1% |
| Q2 FY2020 | Jun 30, 2020 | 114M | +0.1% |
| Q1 FY2020 | Mar 31, 2020 | 114M | +0.1% |
| Q4 FY2019 | Dec 31, 2019 | 113M | +0.1% |
| Q3 FY2019 | Sep 30, 2019 | 113M | +0.0% |
| Q2 FY2019 | Jun 30, 2019 | 113M | -0.0% |
| Q1 FY2019 | Mar 31, 2019 | 113M | -0.2% |
| Q4 FY2018 | Dec 31, 2018 | 113M | -4.9% |
| Q3 FY2018 | Sep 30, 2018 | 113M | -5.4% |
| Q2 FY2018 | Jun 30, 2018 | 113M | -5.9% |
| Q1 FY2018 | Mar 31, 2018 | 114M | -5.6% |
| Q4 FY2017 | Dec 31, 2017 | 119M | -24.7% |
| Q3 FY2017 | Sep 30, 2017 | 120M | – |
| Q2 FY2017 | Jun 30, 2017 | 120M | – |
| Q1 FY2017 | Mar 31, 2017 | 120M | – |
| Q4 FY2016 | Dec 31, 2016 | 158M | – |
See a number that looks wrong?